Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial
COVID-19(IVERCOR-COVID19) 환자의 입원을 방지하기 위한 Ivermectin: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Randomized Controlled Trial
[키워드] 1:1
acute infectious disease
addition
adherence
administration
Admission
adverse event
adverse events
age
allergy
analyzed
Anthropometric data
antiviral drug
antiviral drugs
Arm
ARMS
assessment
barrier
basal
blinded
Breastfeeding
breastfeeding women
Cardiology
Care
care providers
carried
cause
Chain Reaction
childbearing age
Chloroquine
cirrhosis
component
components
Concomitant
Concomitant medication
Confirmed
connection
contraceptive method
contraceptives
Control
control group
control groups
coordination
Corriente
COVID-19
COVID-19 patient population
criteria
current
Day
death
demographic
demographic data
Diagnosis
diagnosis of COVID-19
dialysis
discharged
dissemination
dose
double-blind
drug
Efficacy
Efficacy and safety
elapsed
element
EOS
Equal
example
exclusion criteria
Final
final visit
first dose
Follow-up
greater
heart rate
Hospitalization
hospitalizations
Hydroxychloroquine
incidence
include
Inclusion
inclusion criteria
inclusion/exclusion criteria
Informed consent
Intervention
Invasive mechanical ventilation
investigator
investigators
Ivermectin
Ivermectin safety
Laboratory
less
liver
Liver cirrhosis
Liver disease
mal-absorptive syndrome
medical history
medication
menstrual
menstrual cycles
Mortality
negative
Negative PCR
number
objective
outcome
outcome assessor
outcome assessors
over
oxygen
oxygen saturation
parallel group
participant
Participants
Participation
Patient
patients with COVID-19
PCR
PCR swab
Placebo
placebo-controlled study
polymerase chain
polymerase chain reaction
Polymerase chain reaction test
postmenopausal
pregnant
Presence
Prevent
Primary outcome
protocol
Public
public health
randomization
Randomized
Randomized controlled trial
randomly permuted blocks
receive
recommendation
recorded
recruitment
reducing
renal replacement therapy
replacement therapy
reproductive
required
Research
Sample size
SARS-CoV2
secondary
severe liver disease
single-center
standard treatment
standard treatment alone
Study protocol
supplementary material
surgical
Swab
table
Tablet
temperature
the patient
Total
Treatment
Trial
Trial registration
use of hydroxychloroquine
Version
Viral
viral pathology
Vital
vital signs
vital status
web system
website
weight
woman
women
[DOI] 10.1186/s13063-020-04813-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1186/s13063-020-04813-1 PMC 바로가기 [Article Type] Randomized Controlled Trial